BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Tuesday, March 19, 2024
Home
»
Newsletters
» BioWorld Asia
BioWorld Asia
Jan. 7, 2009
View Archived Issues
Genmab Shares Slide on Interim Zalutumumab Data
Shares in Genmab A/S were off by more than 7 percent during trading Tuesday following an interim update on a Phase III pivotal study of zalutumumab (HuMax-EGFr) in head and neck cancer. (BioWorld International)
Read More
UK/U.S. Program Mapping Chemo Response to Cancers
Read More
Hair Loss Gene has Serendipitous Message for Genetic Sleuths
Read More
UK's Stem Cell Proponents Meeting to Discuss Future
Read More
Small EU Biofirms Benefit from Special Assistance
Read More
Cytos Shares Surge on Pfizer Deal Commitment
Read More
Cellectis Terminates genOway's Homologous Recombination Deal
Read More
Other News To Note
Read More